Bevacizumab in Extensive Small Cell Lung Cancer

NCT00930891 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

143

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Standard Chemotherapy (PCDE or PE)
DRUG: Experimental Treatment (PCDE or PE + bevacizumab)
DRUG: Prerandomization Chemotherapy (PCDE or PE)

Sponsor

Intergroupe Francophone de Cancerologie Thoracique